Neurocrine Biosciences, Inc.
Common Stock · USD · Gettex
Price
$157.198
Cap
—
Earnings
—
30d Trend
+23.4%
33% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 59×Macro 0.99 (−1%)=58
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
3-6 month opportunity — emerging trend
BRAIN47'S ASSESSMENT
I rate Neurocrine Biosciences, Inc. at 58/100 — a STRONG reading on the Brain47 Signal. The strongest factor is quality at 75/100. I classify this as a growth position with the strongest thesis on a medium-term horizon.
PAST PERFORMANCE
1 MONTH
+19.2%
3 MONTHS
+18.3%
12 MONTHS
+26.5%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
3-6 month opportunity — emerging trend. Quality (75) and Technical (69) are the primary strengths. I note that momentum is the weakest area at 41/100 — this warrants monitoring. Historical volatility is moderate at 33%. I classify this as a growth position — positive trend direction combined with solid fundamentals points to capital appreciation.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.